Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
about
Occult HCV Infection: The Current State of KnowledgeLimiting the access to direct-acting antivirals against HCV: an ethical dilemma.Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development.First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohortAsunaprevir, a protease inhibitor for the treatment of hepatitis C infection.Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection.GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection.Asunaprevir-containing regimens for the treatment of hepatitis C virus infection.Drug interactions with new hepatitis C oral drugs.Achieving sustained virological response: what's the impact on further hepatitis C virus-related disease?ABT-450/ ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus.Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis.Beclabuvir for the treatment of hepatitis C.Dual antiviral therapy for HIV and hepatitis C - drug interactions and side effects.Asunaprevir for hepatitis C: a safety evaluation.Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection.Prevention and management of treatment failure to new oral hepatitis C drugs.The therapeutic potential of new investigational hepatitis C virus translation inhibitors.Polymorphisms at IL28B gene as predictors of viral relapse in genotype 4 Egyptian hepatitis C patients.Discontinued drugs in 2012 - 2013: hepatitis C virus infection.Hepatitis B and C.The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C.New hepatitis C therapies for special patient populations.Increased expression and dysregulated association of restriction factors and type I interferon in HIV, HCV mono- and co-infected patients.Clinical value and safety of liver biopsies in patients transplanted for hepatitis C virus-related end-stage liver disease.Ledipasvir/Sofosbuvir administration achieves very high rate of viral clearance in patients with HCV genotype 1 infection without cirrhosis, regardless of ribavirin co-administration or length of treatment.The cost of successful antiviral therapy in hepatitis C patients: a comparison of IFN-free versus IFN-based regimens at an individual patient level in Australia.HCV genotype 3: a wolf in sheep's clothing.
P2860
Q26770595-7B8D9A72-C312-46BF-BFED-370A169888EEQ30244361-F9F81E0F-D5C0-4177-9021-9D40CF58095CQ31051529-53505CA3-2C12-4EF1-98AB-288F5A914CE7Q35164782-3FCF3926-586E-4E10-979E-31FC56DC5D06Q38233860-34749868-CE8F-4817-90AF-1ED9E670D661Q38235178-58D36696-B65D-4B5A-9464-131ACECCEBFFQ38237281-CFF2A721-FF58-45E5-BF04-C42CE06008DBQ38244931-F0FD87D2-1C9D-4CF7-9227-6C3A88A0369AQ38305640-B8C37F0E-2DA4-4D0C-96A0-911BB03DDD4FQ38314738-853EE092-41A2-4FA2-B1BB-BE395982B3C8Q38387667-8CAA4B86-88C4-446D-B270-220BA8195BB0Q38540088-FEB75818-1DED-4EF0-B7D8-6B6538C71516Q38544196-28004F10-9691-48B9-AE65-B9D51864773CQ38554604-4F7DA85A-D2BE-4EBB-A360-D688B069E8A0Q38578458-6506A8CD-3270-44E7-9134-D6718AEB719CQ38626467-68242071-78EB-493C-AA86-2BDFC648044CQ38826624-BA725258-D530-4C26-A664-6FA147AF1064Q38930861-7CE28A8B-E874-4C80-8384-E2650889606DQ38995225-C80CEF6E-FEC0-43C5-8F43-A691DBD53B18Q39100351-72B0C96A-5CAF-4A0A-86BC-1E9F91EC3CD8Q39305112-A63CC454-674B-4B73-96FB-22653A65CAF7Q40326326-A1689078-7B80-4D44-BB0A-1FFEF5901DFBQ40899794-9D6CD686-781C-49B1-921E-628894CE816CQ40929061-01234398-CA00-4244-96C2-52ADA0B5CAF5Q41664208-948BDE3F-ECD1-41C1-853D-B31815129437Q42205980-622BA059-AD29-46E4-AFA9-ED20714ACD3DQ42373161-7EBC9D8C-A3B6-4926-B812-0FF865AE8E2BQ42985723-9694BA36-A3DC-4722-9C62-BEC775082C0F
P2860
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
@ast
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
@en
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
@nl
type
label
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
@ast
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
@en
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
@nl
prefLabel
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
@ast
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
@en
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
@nl
P2860
P50
P1476
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
@en
P2093
Antonio Riccardo Buonomo
P2860
P304
P356
10.1586/14787210.2014.929497
P577
2014-07-01T00:00:00Z